Company Overview of Regen BioPharma Inc.
Regen Biopharma, Inc., a biotechnology company, focuses on the development of regenerative medical applications in the United States. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrow; HemaXellerate II, a donor endothelial cell based therapeutic product; and dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer. The company was founded in 2012 and is based in La Mesa, California. Regen Biopharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.
4700 Spring Street
La Mesa, CA 91942
Founded in 2012
Key Executives for Regen BioPharma Inc.
Chairman, Chief Executive Officer, President, Principal Accounting Officer, Chief Executive Officer of Bio-Matrix Scientific Group, Treasurer, Secretary, Chairman of Bio-Matrix Scientific Group and Director of Bio-Matrix Scientific Group
Total Annual Compensation: $300.0K
Chief Scientific Officer, Director of Research and Director
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2014.
Regen BioPharma Inc. Key Developments
Regen BioPharma Inc. Declares Dividend on Common Shares, Payable on or About March 20, 2015
Feb 24 15
On February 18, 2015 the Board of Directors of Regen BioPharma Inc. declared a dividend to common shareholders of record as of March 10, 2015 to be paid to common shareholders on or about March 20, 2015.
Regen Biopharma, Inc. Appoints Todd S. Caven as Chief Financial Officer
Feb 13 15
On February 11, 2015 the board of directors of Regen Biopharma Inc. appointed Mr. Todd S. Caven, to the position of Chief Financial Officer of Regen. Mr. Caven currently serves as Managing Member of both Rock Ridge Enterprises LLC and Saguaro Capital Partner LLC, where he is solely responsible for making investment decisions on behalf of each company. Prior to that Mr. Caven was the founder and served as Chief Financial Officer of Obstetric Solutions and Interventions where his duties included raising capital for the company, as well as maintaining the financial records of the company.
Regen Biopharma Inc. Identifies Second Generation Gene Silencing Candidates for Blocking Cancer Stem Cell Gene Target
Jan 8 15
Regen BioPharma Inc. announced the discovery and demonstration of in vitro efficacy of a second generation of gene silencing drug candidates with specificity to the cancer stem cell gene NR2F6. The Company has rights to an invention covered by a non-provisional patent application disclosing compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation. The patent covers the use of its proprietary novel candidates administered as short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA). Proof-of-concept studies originally identifying NR2F6 as a target for cancer stem cells were performed by Dr. Christine Ichim, senior research consultant with Regen Biopharma, along with scientists at the University of Toronto. These studies showed that silencing of the NR2F6 gene in leukemia cells led to the cells losing their leukemic characteristics. Cancer stem cells, also known as the cancer initiating cells, are the cells in a cancer that are tumorigenic, meaning they have the ability to cause formation of new tumors when implanted in animals. Blocking their ability to self-renew by silencing NR2F6 transforms cancer cells in to a non-tumorigenic state by guiding cells toward a process called differentiation and cellular maturation.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 29, 2015
January 22, 2015